Rebecca Knutsen

Imagine you’ve hired a contractor to renovate your kitchen and a curtain is hung on the threshold, completely hindering your ability to see the project. You’re told that the curtain will be opened once a month so you may note progress. For the rest of each month, you’re left wondering whether any work is being done, if the project has hit snags, and if you approve of the project’s direction. I can think of few individuals who would stand for this type of arrangement and yet, until quite recently, that’s the way many CRO-sponsor relationships have functioned. (ghostwriting for ERT)

While we’ve all heard that developing a new drug costs more than $2 billion, the average cost of a Phase 3 clinical trial (across all therapeutic areas) is roughly $21 million over the course of about two years. (ghostwriting for ERT)

Orphan drugs often spell big profits for manufacturers, and unmet medical needs mean many camps are clamoring to quickly shuttle products to market.

Roche gears up to enter loaded hemophilia A drug ma...

A handful of anticipated branded products that gained FDA approval in the generics-dominated cardiovascular disease space have garnered barely audible post-launch applause. These treatments, both novel ones and me-toos, are being met with payer resistance, prescriber uncertainty, and pricing problems.

Despite their blockbuster status and distinction as the world's most widely prescribed class of drugs, statins may not be the best option for all patients with elevated low density lipoprotein (LDL) cholesterol levels.

Artificial Intelligence is Pharma’s Next Frontier in Customer Relationships
(ghostwriting)

The crop of late-stage biopharmaceutical agents angling for an FDA stamp of approval may find itself in one of the most challenging commercial climates in decades.

Even one leak—while seemingly small—can have damaging effects on a company’s financial health. Oncology practices are no different. (ghostwriting)

Companies must strike the right balance in data governance and reflect its importance through well-trained data stewards. (ghostwriting)

If the field of healthcare analytics had an elevator pitch, it would read something along the lines of: Data crunching has the power to add value to patient care. (ghostwriting for IMS Health)

Home Remodeling Magazine - Home Remodeling Magazine...

AmerisourceBergen: Experts address the impact of impending Medicare Part B policy changes (ghostwriting).

IMS Health Gathers Panel of Life Sciences Experts to Discuss the Ripple Effects of Transforming Technology (marketing writing for IMS Health)

Breaking down big data. (Ghostwriting for AmerisourceBergen)